anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lidocaine
Trial phase: Phase 4
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Participants may be randomized to receive Lidocaine for their TPI.

Lidocaine: Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Eligibility criteria:
Inclusion Criteria:

Men or women age 18 or over
At least one active trigger point

Exclusion Criteria:

Allergy or contraindication to any NSAID, CS, or local anesthetic
Receiving anticoagulant medication
History of bleeding disorder
Pregnant or breast feeding women
Gastrointestinal ulceration
Pre-existing renal disease
Pre-existing congestive heart failure
Diabetes mellitus
Prior myocardial infarction or stroke
Fibromyalgia
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Participants may be randomized to receive Dexamethasone for their TPI.

Dexamethasone: Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Eligibility criteria:
Inclusion Criteria:

Men or women age 18 or over
At least one active trigger point

Exclusion Criteria:

Allergy or contraindication to any NSAID, CS, or local anesthetic
Receiving anticoagulant medication
History of bleeding disorder
Pregnant or breast feeding women
Gastrointestinal ulceration
Pre-existing renal disease
Pre-existing congestive heart failure
Diabetes mellitus
Prior myocardial infarction or stroke
Fibromyalgia
Intervention: Byetta
Trial phase: Phase 4
ATC code: A10BJ01
SMILES: CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(N)Cc1c[nH]cn1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.

Exenatide Extended Release for Inj Susp 2 MG: Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
Eligibility criteria:
Inclusion Criteria:

Type 2 Diabetes for at least 1 year.
Microalbuminuria for at least 6 months (UACR: 30-300 mg/g)
Macroalbuminuria for at least 6 months (UACR: >300 mg/g)
HbA1c of ≤10%
Ages 18-65 years (inclusive of ages 18 and 65)
On ARBs/ACEi for at >3months

Exclusion Criteria:

Use of GLP-1 Receptor agonists or SGLT-2 inhibitors therapy in the last 3 months
History or risk for pancreatitis (e.g., history of gallstones, alcohol abuse, and hypertriglyceridemia)
Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous 3 months

Hepatic disease: Severe hepatic insufficiency and/or significant abnormal liver function defined as:

Aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN
Total bilirubin >2.0 mg/dL (34.2 µmol/L)
Positive serologic evidence of current infectious liver disease including Hepatitis B viral antibody IGM, Hepatitis B surface antigen and Hepatitis C virus antibody
Liver function tests more than 3 times the upper limit of normal
Renal impairment (serum eGFR <30 ml/min)
HIV
Inability to give informed consent
History of gastroparesis
History of medullary thyroid carcinoma or MEN 2 syndrome
Alcoholism
Hypertriglyceridemia (>500 mg/dl).
Any other life-threatening, non-cardiac disease
Uncontrolled hypertension (BP > 160/100 mm of Hg)
Congestive Heart Failure class III or IV
Use of an investigational agent or therapeutic regimen within 30 days of study
Participation in any other concurrent clinical trial
Pregnant or breastfeeding patients or females of childbearing age not on 2 forms of acceptable contraceptives.
Intervention: Zilucoplan
Trial phase: Phase 2
ATC code: L04AJ06
SMILES: CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ncccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N(C)C(=O)[C@@H]1CC(=O)NCCCC[C@H](NC(C)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(C)(C)C)C1CCCCC1)C(=O)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Subjects will receive zilucoplan (RA101495) at the dose of 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC

Zilucoplan (RA101495): 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
Eligibility criteria:
Inclusion Criteria:

Diagnosis of PNH by flow cytometry
Inadequate response to eculizumab defined as having received eculizumab for at least 6 months plus a documented LDH level ≥ 1.5 x the upper limit of normal (ULN) and/or the presence of a known C5 mutation conferring resistance to eculizumab

Exclusion Criteria:

History of meningococcal disease
Current systemic infection or suspicion of active bacterial infection
Intervention: OXYBATE
Trial phase: Phase 3
SMILES: O=C(O)CCCO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 201
Group description: JZP-258 at the dose taken during the last 2 weeks of the Stable Dose Period.
Eligibility criteria:
Inclusion Criteria:

Male or female subjects between 18 and 70 years of age, inclusive.
Have a primary diagnosis of narcolepsy with cataplexy that meets ICSD-3 criteria or DSM-5 criteria, and currently untreated or treated with or without anticataplectics.
If applicable, treated with a stimulant or alerting agent at unchanged doses for at least 2 months prior to dosing or not treated with a stimulant or alerting agent.
Willing and able to comply with the study design schedule and other requirements.
Willing and able to provide written informed consent.

Exclusion Criteria:

Narcolepsy secondary to another medical condition (e.g., CNS injury or lesion)
History or presence of any unstable or clinically significant medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or history or presence of another neurological disorder or surgical history that might affect the subject's safety and/or interfere with the conduct of the study in the opinion of the Investigator.
Treatment with any central nervous system sedating agents, including but not limited to benzodiazepines, nonbenzodiazepine anxiolytics/ hypnotics/sedatives, neuroleptics, opioids, barbiturates, phenytoin, ethosuximide, or MCT inhibitors, e.g. diclofenac, valproate, ibuprofen, within 2 weeks prior to enrollment (discontinuation for the purpose of study enrollment is permitted only if considered safe by the Investigator and approved by the Medical Monitor).
Treatment with an antidepressant for cataplexy, if the withdrawal of the antidepressant during cross-titration with JZP-258 might be unsafe due to prior history of depression.
Unsafe for the subject to receive placebo treatment for 2 weeks, in the opinion of the Investigator.
Intervention: Pregabalin
Trial phase: Phase 3
ATC code: N02BF02 | N03AX16
SMILES: CC(C)C[C@H](CN)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Pregabalin: On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
Eligibility criteria:
Inclusion Criteria:

Age : > 18 years old
Fusion of > two vertebrae
Capacity to provide consent
ASA I-IV
Ability to swallow capsules

Exclusion Criteria:

Plan of care includes intubated ICU admission post-op
Allergy to gabapentin or pregabalin
Two week prior use of pregabalin
Significant renal dysfunction (creatinine level >2)
Severe cardiovascular disease
History of frequent headaches or dizziness
Significant hepatic dysfunction (LFT's > 4 times the normal ranges)
Active usage of alcohol or illicit substances three days prior to surgery
History of seizure disorders
Taking medication for anxiety, antiseizure, and psychiatric diagnoses
Re-operation patients
Intervention: Ketorolac
Trial phase: Phase 4
ATC code: M01AB15 | S01BC05 | S01FB51
SMILES: O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 71
Group description: ketorolac, oral, 20 mg, 1 dose, 45 minutes prior to IUD placement

Ketorolac: Oral Tablet
Eligibility criteria:
Inclusion Criteria:

non-pregnant
English speaking women
18 years of age or older desiring an IUD for contraception

Exclusion Criteria:

enrollment in another study
pre-medication with any type of analgesic medication
contraindication to an IUD
weight under 50 kg
allergy to non-steroidal anti-inflammatory medications
past medical history of liver disease, renal disease, peptic ulcer disease or recent gastrointestinal bleed,
daily narcotic pain use
positive cultures for gonorrhea or chlamydia.
Intervention: Isoprenaline
Trial phase: Phase 2
ATC code: C01CA02 | R03AB02 | R03AK02 | R03CB01 | R03CB51
SMILES: CC(C)NCC(O)c1ccc(O)c(O)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 68
Group description: This group will not receive adenosine during the procedure.

Isoproterenol: Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
Eligibility criteria:
Inclusion Criteria:

Patients >18 and <75 who are able to give informed consent undergoing atrial fibrillation ablation procedure.
Paroxysmal Atrial fibrillation lasting = 7 days which is self-terminating. It is considered recurrent if two or more episodes occur.
Failure or unwilling to take class I or III anti-arrhythmic drugs

Exclusion Criteria:

History of asthma
Patients with severe coronary artery disease, stable/unstable angina, or ongoing myocardial ischemia
Previous cardiac surgery ( excluding CABG and mitral valve surgery)
Symptomatic congestive heart failure including but not limited to NYHA III/IV and/or documented ejection fraction <40% measured by acceptable cardiac testing,
Left atrial diameter >55mm
Moderate to severe mitral or aortic valve disease
Myocardial infarction within three months of enrollment
Congenital heart disease where it increases the risk of an ablative procedure
Prior ASD/PFO closure with a device using a percutaneous approach
Hypertrophic cardiomyopathy (LV wall thickness >1.5mm)
Pulmonary Hypertension (mean or systolic PA pressure> 50mmHg on Doppler echocardiography
Any prior ablation of atrial fibrillation
Enrollment in any other arrhythmia protocol
Any ventricular arrhythmia being treated where the arrhythmia or management may interfere with this study
Active infection or sepsis
Any history of cerebrovascular disease including stroke or TIAs
Pregnancy or lactation
Left atrial thrombus at the time of ablation
Untreatable allergy to contrast media
Any diagnosis of atrial fibrillation secondary to electrolyte disturbance, thyroid disease, or any other reversible or non-cardiovascular causes
History of blood clotting(bleeding or thrombotic) abnormalities
Known sensitivities to heparin or warfarin
Severe COPD (defined as FEV1 <1)
Severe comorbidity or poor general physical/mental health that, in opinion of the investigator, will not allow the patient to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, shortened life expectancy)
Intervention: Dorzolamide Hydrochloride
Trial phase: Phase 2 | Phase 3
SMILES: CCNC1CC(C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.

Dorzolamide-timolol: Topical eye drop (active comparator) used twice daily for study duration
Eligibility criteria:
Inclusion Criteria:

Active choroidal neovascularization (CNV) due to AMD.
Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during this period.
Baseline CST ≥ 270 µm on SD-OCT automated retinal thickness map.
Injection of the same anti-VEGF agent at each of the two visits immediately preceding study enrollment.
Time interval of 5 weeks (± 1 week) between visits for at least two visits immediately preceding study enrollment.
Subjects of either gender aged ≥ 45 years.
Provide written informed consent
Ability to comply with study and follow-up procedures and return for study visits.

Exclusion Criteria:

History of uveitis.
Presence of intraocular inflammation, significant epiretinal membrane (causing distortion of macular anatomy per investigator discretion), significant vitreomacular traction (per investigator discretion), macular hole, or vitreous hemorrhage.
Any ophthalmic surgery within previous 6 months, including cataract extraction.
Any history of vitrectomy or glaucoma surgery (e.g., trabeculectomy, tube shunt).
Current prescription eye drop usage (e.g., glaucoma drops, corticosteroid drops, etc.).
Any contraindication for topical use of a beta-blocker (e.g., bradycardia, decompensated heart failure, chronic obstructive pulmonary disease, reactive airway disease, asthma, etc.).
Any history of sulfonamide allergy.
Intervention: Leuprolide
Trial phase: Phase 4
ATC code: L02AE02 | L02AE51
SMILES: CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 106
Group description: Participants received 22.5 mg of leuprolide acetate (eligard) by subcutaneous injection at baseline, month 3, 6, 9, 12 and 15.
Eligibility criteria:
Inclusion Criteria:

A patient for whom the physician has decided to initiate treatment with a Luteinizing Hormone Releasing Hormone (LHRH) agonist in standard clinical practice
Biopsy-proven prostate adenocarcinoma
Locally advanced prostate cancer with biochemical relapse radical prostatectomy and/or radiotherapy, OR hormonal treatment-naive advanced or metastatic prostate cancer patient who has not received chemotherapy and has no plans to undergo treatment with chemotherapy at study entry.
Patient who indicates that once the study is completed, he expects having access to androgen deprivation therapy (ADT), either medical or surgical, within the local healthcare system (either through public/ private health insurance or out of pocket payment).

Exclusion Criteria:

Patient with castrate resistant prostate cancer
Patient who previously underwent bilateral orchiectomy
Patient who has received prior treatment with LHRH analogues
Prior or concomitant treatment with systemic chemotherapy. A patient where there is a likelihood to receive systemic chemotherapy should not be enrolled
Life expectancy of < 1 year due to comorbidities
Participation in another interventional clinical trial within one month prior to study entry or during the duration of the study
Patient who plans to receive intermittent ADT at the time of study entry
Patient receiving non-palliative radiotherapy within 3 months prior to study entry
Patient receiving adjuvant ADT in combination with definitive radiotherapy
Patient with metastatic hormonal treatment-naive prostate cancer, for whom chemo-hormonal treatment (combination of Docetaxel and ADT) is indicated.
Patient with hypersensitivity to gonadotropin releasing hormone (GnRH), GnRH agonist analogs or any of the components of ELIGARD®
Patient with any contraindication for ELIGARD® use based on local prescribing information
Intervention: Varenicline
Trial phase: Phase 1 | Phase 2
ATC code: N07BA03 | S01XA28
SMILES: c1cnc2cc3c(cc2n1)C1CNCC3C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: 1 mg BID (2 capsules BID)

Varenicline: 1 mg BID
Eligibility criteria:
Inclusion Criteria:

To be eligible, the subject must:

Be at least 21 years of age.
Meet the DSM 5 criteria for alcohol use disorder of a least moderate severity (AUD-MS).
Be seeking treatment for AUD and desire a reduction or cessation of drinking.
Be able to verbalize an understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.

Agree (if the subject is female and of child bearing potential) to use at least one of the following methods of birth control, unless she is surgically sterile, partner is surgically sterile or she is postmenopausal:

oral contraceptives,
contraceptive sponge,
patch,
double barrier (diaphragm/spermicidal or condom/spermicidal),
intrauterine contraceptive system,
levonorgestrel implant,
medroxyprogesterone acetate contraceptive injection,
complete abstinence from sexual intercourse, and/or
hormonal vaginal contraceptive ring.
Be able to take oral medication and be willing to adhere to the medication regimen.
Complete all assessments required at screening and baseline.
Have a place to live in the 2 weeks prior to randomization and not be at risk that s/he will lose his/her housing in the next 2 months.
Not anticipate any significant problems with transportation arrangements or available time to travel to the study site over the next 2 months.
Not have any unresolved legal problems that could jeopardize continuation or completion of the study.
And others.

Exclusion Criteria:

Contact site for additional information
Intervention: 3,5-Dideoxy-5-[(Hydroxyacetyl)amino]-D-Glycero-D-Galacto-Non-2-Ulosonic Acid
Trial phase: Phase 2
SMILES: O=C(CO)NC(C(O)CC(=O)C(=O)O)C(O)C(O)C(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 115
Group description: Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily

rhNGF: Eye Drop 20 μg/mL
Eligibility criteria:
Inclusion Criteria:

Male or female ≥18 years old

Patients who are characterized by the following clinical features:

History of cataract or refractive corneal surgery in the study eye(s) in the previous 6 months;
Mean Symptom Assessment in Dry Eye (SANDE) score for severity and frequency of at least 30 at baseline
The same eye (study eye) must fulfill all the above criteria
Best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units in both eyes at the time of study enrolment
Female patients must have negative pregnancy urine test if at childbirth potential.
Only patients who satisfy all requirements for informed consent may be included in the study. Written Informed Consent must be obtained before the initiation of any study-specific procedures.
Patients must have the ability and willingness to comply with study procedures

Exclusion Criteria:

Any ocular disease other than Dry Eye requiring treatment with topical medications in either eye at the time of study enrolment.
Any active ocular infection or active inflammation in either eye unrelated to Dry Eye.
Presence or history of any systemic or ocular disorder, condition or disease (with particular attention to malignancies and neuro-oncological diseases) that could possibly interfere with the conduct of the required study procedures or the interpretation of the study results.
Use of therapeutic or Refractive Contact lenses in either eye at the time of study enrolment;
History of ocular surgery in the study eye(s), excluding corneal refractive or cataract procedures, within 90 days of study enrolment.

Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:

are currently pregnant or,
have a positive result at the urine pregnancy test (Baseline/Day 0) or,
intend to become pregnant during the study treatment period or,
are breast-feeding or,
are not willing to use highly effective birth control measures, such as: hormonal contraceptives - oral, implanted, transdermal, or injected - and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD (Intrauterine device) - during the entire course of and 30 days after the study treatment periods.
Participation in another clinical study at the same time as the present and within 30 days of study enrolment;
History of drug, medication or alcohol abuse or addiction.
Intervention: Betamethasone
Trial phase: Phase 1
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Healthy subjects will be enrolled and each will undergo study procedures at three study visits.

All subjects will undergo the same procedures and interventions.

Dexamethasone: A single dose of dexamethasone IV 4 mg will be administered.
Eligibility criteria:
Inclusion criteria:

Men and women ages 18-50 years
BMI 18.5 to <25 kg/m^2

Exclusion Criteria:

Significant use of systemically-absorbed glucocorticoids currently or for an extended period of time during the prior 6 months
Current use of antihypertensive medications
Current use of metformin, or any antidiabetic medications (which could affect glucose and insulin levels)
Current use of medications known to affect dexamethasone metabolism, including phenytoin, rifampin, carbamazepine, troglitazone, and barbiturates
Active, clinically significant infection at time of visit
History of adrenal insufficiency or Cushing's syndrome
Prior or current cardiovascular disease, renal disease, or liver disease
Diabetes mellitus, pre-diabetes, impaired fasting glucose, or impaired glucose tolerance
Atrial fibrillation
Bleeding disorder or anemia
Elevated Liver Functions Tests > 2 times upper limit of normal
Estimated glomerular filtration rate < 60 ml/min
HbA1c > 5.7
Abnormal sodium or potassium level
Positive pregnancy test, women of child-bearing age not practicing birth control, women who are breastfeeding